Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
An image of a syringe and a vaccine. AstriVax received a €2.5 million government grant that will be used to fund its vaccine platform. Image Credit: Shutterstock / LookerStudio
AstriVax has received a €2.5 million government grant from the Flanders Innovation & Entrepreneurship (VLAIO) agency that will be used to fuel the company’s vaccine platform, per a 30 May announcement. How is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Report.
VLAIO is a Flemish government agency that seeks to promote entrepreneurship and research through funding and advice. The funding will go towards the further optimisation of AstriVax’s technology and its subsequent study in the clinic. This follows a past €30 million seed capital round that was announced in August 2022. The seed capital round was led by the Belgian venture capital firm V-Bio Ventures and Fund+. The Leuven, Belgium-headquartered company AstriVax will use this funding to bring its yellow fever vaccine into the clinic and develop its jabs for rabies and chronic hepatitis B, based on an August 2022 announcement. The company is a spin-off of the Belgian university KU Leuven and is cofounded by researchers from the university’s Rega Institute. The company’s platform is based on work done by a consortium led by KU Leuven. The company’s prophylactic yellow fever vaccine is part of its plasmid-launched live attenuated virus (PLLAV) platform. AstriVax’s vaccines based on this platform are thermostable, which means their properties do not change due to the heat. This would help address some of the challenges that vaccine producers face with cold chain management where products need to be kept at low temperatures, a topic that was widely discussed during the rollout of Covid-19 vaccinesCovid-19 vaccines. The company’s thermostable technology will eventually allow for the vaccines’ easier distribution across the world, including in warmer, tropical regions, per the company’s August 2022 release. AstriVax’s yellow fever vaccine remains in a preclinical proof-of-concept stage of development. Additionally, the company is also developing its prophylactic rabies vaccine, which is designed to give dual protection and is also in the preclinical stage. Outside of the prophylactic vaccine pipeline, the company is also researching a potential therapeutic vaccine candidate for chronic hepatitis B. This vaccine is aimed to serve as part of a potential combination therapy and has previously induced specific CD8+ T cells. How is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Report.